Medication info
Lidipom Extended Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Lidipom Extended Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
Oval extended release tablet, white to almost white, engraved with L5M on one side
Packaging
28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle
Approval status
Active

MFDS item code 202400623 · Approved 2024.03.22 · Insurance code 645907540

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood glucose in patients with type 2 diabetes through the combined use of linagliptin and metformin. Patients can effectively manage their blood glucose levels by taking this medication alongside dietary and exercise therapy. This combination treatment improves blood glucose management and helps prevent complications from diabetes. Therefore, it is appropriately used for blood glucose control in patients with type 2 diabetes.

How to take

Adult dose

The dose of this medicine for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride, as extended-release, 2000 mg. This medicine should be taken with food once daily, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. For this medicine 5/1000 mg extended-release tablets, take 1 tablet once daily. Patients taking this medicine 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: The initial dose of this medicine is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin therapy - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medicine consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medicine is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution). - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Because dose adjustment according to renal function may be necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this medicine may be used with metformin hydrochloride dose adjustment as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin hydrochloride is 500mg or 750mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This medication may cause a rare side effect called lactic acidosis, therefore caution is required. It should not be administered to patients with severely impaired renal function or those in a state of severe infection or dehydration. Patients with allergies to this medication or those with type 1 diabetes or diabetic ketoacidosis should also avoid use. Patients with severely impaired cardiac function or liver dysfunction should also refrain from using this medication. It should not be used during pregnancy or in cases of acute alcohol intoxication. This medication carries a risk of hypoglycemia; thus, when used with insulin or sulfonylureas, blood glucose must be closely monitored. Symptoms of lactic acidosis include difficulty breathing, weakness, and abdominal pain, and if such symptoms occur, the doctor must be notified immediately. Renal function is crucial, and regular kidney function tests should be performed before and during treatment, and the medication should be discontinued if renal function declines. If iodinated contrast is used for radiological tests, this medication should be suspended for a certain period before and after the tests, and renal function should also be re-evaluated. Patients scheduled for surgery should discontinue this medication 48 hours prior to surgery and resume it once renal function is normal after the surgery. While taking this medication, rare side effects such as acute pancreatitis or skin vesicles resembling bullous pemphigoid may occur, so any symptoms should be reported immediately. This medication should be swallowed whole without crushing or chewing, and it is normal for the tablet coating to pass out in stool. Long-term use may lead to vitamin B12 deficiency, so regular blood tests may be required. This medication may interact with several other medications; therefore, if other medications are being taken, one must consult a physician or pharmacist. Elderly patients are commonly prone to impaired renal function, therefore dosing adjustments and monitoring of kidney function are particularly important. It is not recommended for use during pregnancy or breastfeeding without consulting healthcare professionals. Overdose may result in serious side effects such as lactic acidosis, necessitating immediate hospital treatment. This medication should be stored out of reach of children and kept away from moisture, avoiding transfer to other containers.

Side effects

Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reaction, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, itching, erythema, rash, dermatitis herpetiformis, severe joint pain accompanied by disability, rhabdomyolysis, increased lipase levels, increased amylase, constipation, upper abdominal pain, enterocolitis, bowel obstruction, gastroenteritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuritis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's-type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, colorectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, dizziness, kidney transplant failure, viral upper respiratory infection, upper respiratory infection, gastroenteritis, shingles, cystitis, vertigo, sensory loss, chest discomfort, weakness, nosebleeds, oropharyngeal pain, vocal disorders, allergic rhinitis, exertional dyspnea, wet cough, runny nose, pulmonary mass, joint pain, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, increased ALT, male pattern baldness, hyperhidrosis, dermatitis, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, gastritis, nosebleeds, stomatitis, vitreous hemorrhage, confusion, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, and should therefore be stored in a sealed container. Additionally, for safe use of the medication, it is best to store it at room temperature between 1°C and 30°C.

Appearance and packaging

Appearance

Oval extended release tablet, white to almost white, engraved with L5M on one side

Package unit

28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.